A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)

被引：0
|
作者：
Rosenberg, Jonathan
Sabatier, Renaud
Viceneux, Armelle
Rouge, Thibault De la Motte
Champiat, Stephane
Lebellec, Loic
Barthelemy, Philippe
Sonpavde, Guru
Gao, Xin
Niglio, Scot
Zhang, Tian
Gedye, Craig
Galsky, Matthew
Milowsky, Matthew
Reimers, Melissa
Weickhardt, Andrew
Grande, Enrique
Castellano, Daniel E.
Bilen, Mehmet
Patnaik, Amita
Zerbib, Robert
Balbas, Minna
Xu, Xiaojian
Aptaker, Kaitlyn
Balar, Arjun V.
Awada, Ahmad H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT084
引用
收藏
页数：2
相关论文
共 50 条
  • [1] NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)
    Baldini, C.
    Patnaik, A.
    Lakhani, N.
    Call, J.
    Galsky, M.
    Garmezy, B.
    Wei, A.
    Carter, L.
    Powles, T.
    Siefker-Radtke, A.
    O'Donnell, P. H.
    Kitano, S.
    Castellano, D. E.
    Shinde, R.
    Joshua, A. M.
    Balbas, M.
    Han, H.
    Chang, A. E.
    Gao, X.
    Iyer, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S66 - S66
  • [2] Preclinical characterization of ETx-22, a next-generation antibody drug conjugate (ADC) targeting nectin-4
    Azim, Hatem
    Lhospice, Florence
    Preville, Xavier
    Fares, Joanna
    Lopez, Marc
    Crompot, Emerence
    Josselin, Emmanuelle
    Castellano, Remy
    Wehbeh, Maria
    Collette, Yves
    Elands, Jack
    Olive, Daniel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [3] ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors
    Lopez, Marc
    Crompot, Emerence
    Josselin, Emmanuelle
    Farina, Anne
    Rubis, Marion
    Castellano, Remy
    Fares, Joanna
    Wehbe, Maria
    Collette, Yves
    Charafe, Emmanuelle
    Blanchin, Stephanie
    Romagne, Francois
    Palfi, Aniko
    Hechler, Torsten
    Pahl, Andreas
    Azim Jr, Hatem A.
    Lhospice, Florence
    Mamessier, Emilie
    Bertucci, Francois
    Elands, Jack
    Preville, Xavier
    Olive, Daniel
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (11): : 2998 - 3012
  • [4] Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
    Zhang, J.
    Liu, R.
    Gao, S.
    Li, X.
    Chen, J.
    Yao, X.
    Fang, Y.
    Li, R.
    Zhang, M.
    Qiu, F.
    Li, Y.
    Liu, T.
    Huang, H.
    Zhang, X.
    Guo, H.
    Hu, B.
    Liu, J-Y.
    Yang, Q.
    Zhao, P.
    Wang, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S464 - S464
  • [5] 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Yang, Huijuan
    Chen, Jian
    Yuan, Fang
    Liu, Jiyan
    Guo, Hongqian
    Zhang, Shun
    Li, XingYa
    Yao, Xin
    Bai, Ming
    Bu, Hualei
    Li, Yinyin
    Hu, Changlu
    Li, Xiumin
    Wang, Zhen
    Wang, ShanBing
    Lou, Hanmei
    Feng, Zhe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Development of AGS-22M6E, a novel antibody drug conjugate (ADC) targeting Nectin-4 for the treatment of solid tumors
    Satpayev, Daulet
    Torgov, Michael
    Yang, Peng
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Art
    Liu, Wendy
    Lortie, Dawn
    An, Zili
    Capo, Linnette
    Leavitt, Monica
    Perez, Myra
    Verlinsky, Alla
    Shirasuna, Kenna
    Avina, Hector
    Guevara, Claudia
    Morrison, Kendall
    Challita-Eid, Pia
    Jia, Xiao-Chi
    Gudas, Jean
    Stover, David
    CANCER RESEARCH, 2011, 71
  • [7] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
    Tolcher, A. W.
    Calvo, E.
    Maitland, M. L.
    Gibson, B.
    Xuan, D.
    Joh, T.
    Jackson-Fischer, A.
    Damelin, M.
    Barton, J.
    Xin, X.
    Sachdev, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
  • [8] A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial
    Ma, Yuxiang
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Xue, Jinhui
    Meng, Xiangjiao
    Fan, Yun
    Fu, Siqing
    Wu, Lin
    Zheng, Yulong
    Liu, Jian
    Liu, Zhihua
    Zhuang, Wu
    Rosen, Seth
    Qu, Song
    Li, Bihui
    Li, Mingjun
    Zhao, Yanqiu
    Yang, Shujun
    Ji, Yinghua
    Sommerhalder, David
    Luo, Suxia
    Yang, Kunyu
    Li, Jingao
    Lv, Dongqing
    Zhang, Peng
    Zhao, Yuanyuan
    Hong, Shaodong
    Zhang, Yang
    Zhao, Shen
    Chin, Steve
    Zhang, Xian
    Lian, Wei
    Cai, Jiaqiang
    Xue, Tongtong
    Zhang, Li
    Zhao, Hongyun
    NATURE MEDICINE, 2025,
  • [9] Efficacy and safety of 9 MW2821, an antibody-drug conjugate targeting Nectin-4 monotherapy, in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, phase I/II study
    Yang, Huijuan
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Lou, Hanmei
    Li, Guiling
    Bu, Hualei
    Li, Rong
    Wang, Shanbing
    Shen, Shujing
    Zhang, Mingjun
    Wang, Peipei
    Feng, Zhe
    Chu, Nan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S22 - S23
  • [10] Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.
    Tang, Bixia
    Sheng, Xinan
    Guo, Jun
    Niu, Haitao
    Shen, Yali
    Jiang, Shusuan
    Fu, Bin
    Guo, Jianming
    Wahafu, Wasilijiang
    Yao, Kai
    Liu, Nan
    Gu, Jiang
    Chen, Yu
    Li, Zhenhua
    Lin, Tianxin
    Ma, Liping
    Lin, Jiaqin
    Zhang, Chi
    Wang, Wenliang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345